by Pulmonary edema therapeutics are medical aids used for the treatment of pulmonary edema, a fluid build-up in the lungs. Pulmonary edema occurs when fluid leaks into air spaces and sacs (alveoli) in the lungs, making it difficult to breathe. Some common causes of pulmonary edema include heart failure, fluid overload from kidney disease, infection in lungs, physical trauma, exposure to toxic chemicals, or high altitude sickness. Pulmonary edema therapeutics involve drugs such as diuretics that remove excess fluid from the body and reduce fluid buildup in the lungs. Other therapeutics include oxygen therapy to help improve oxygen levels and breathing difficulties.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 13,990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of pulmonary edema due to rising incidence of heart failure, lung infections, and high-altitude pulmonary edema is a major driver boosting the growth of the global pulmonary edema therapeutics market. Heart failure is one of the leading causes of pulmonary edema. According to the American Heart Association’s Heart Disease and Stroke Statistics – 2022 Update, nearly 6.2 million adults in the U.S. have heart failure. The number is projected to increase 46% to over 8 million by 2030. Rising cases of heart failure, in turn, are expected to drive the demand for pulmonary edema therapeutics over the forecast period.
Segment Analysis
The global Pulmonary Edema Therapeutics market is segmented based on drug class into diuretics, oxygen therapy, vasodilators, and others. The diuretics segment currently dominates the market due to high prevalence of heart failure and high blood pressure. Nearly all patients with pulmonary edema are initially treated with loop diuretics such as furosemide that help eliminate excess fluid from the lungs and body by increasing sodium excretion through urine.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market Demand is expected to witness high growth. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 13,990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031.
North America currently holds the largest share in the pulmonary edema therapeutics market owing to high healthcare expenditure and increasing prevalence of lifestyle diseases in countries like the US. Asia Pacific is expected to witness the highest growth during the forecast period due to large patient population, increasing healthcare penetration, and growing geriatric population.
Key players operating in the Pulmonary Edema Therapeutics market are Knoll Inc., Freudenberg Group, Avgol Ltd., Carnegie Fabrics LLC, Eximius Incorporation, Berry Global Group Inc., Asahi Kasei Corporation, Ahlstrom Munksjo OYJ, Kimberly-Clark Corporation, and Paramount Tech Fab Industries. Existing players in the market are focusing on new product approvals and launches to expand their product portfolio and strengthen market position. For instance, in January 2022, US FDA approved Knoll Inc.’s supplemental new drug application to expand the use of Xcopri (cenobamate tablets) for the treatment of partial-onset seizures in adults with epilepsy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
